Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.

Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council..

Stroke. 2009 Aug;40(8):2945-8. doi: 10.1161/STROKEAHA.109.192535. No abstract available. Erratum in: Stroke. 2010 Sep;41(9):e562.

2.

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.

Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention..

Stroke. 2016 Feb;47(2):581-641. doi: 10.1161/STR.0000000000000086. Review. Erratum in: Stroke. 2016 Nov;47(11):e262.

3.

Role of tissue plasminogen activator in acute ischemic stroke.

Hatcher MA, Starr JA.

Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Review.

PMID:
21386027
4.

Treatment of acute ischemic stroke: intravenous and endovascular therapies.

Jahan R, Vinuela F.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):375-87. doi: 10.1586/erc.09.13. Review.

PMID:
19379062
5.
6.

Recombinant tissue plasminogen activator for acute ischemic stroke.

Al-Buhairi AR, Jan MM.

Saudi Med J. 2002 Jan;23(1):13-9. Review.

PMID:
11938357
7.

Thrombolysis for acute ischemic stroke.

Uyttenboogaart M, De Keyser J, Luijckx GJ.

Curr Top Med Chem. 2009;9(14):1285-90. Review.

PMID:
19849662
8.

Management of acute ischemic stroke: time is brain.

Rymner MM, Akhtar N, Martin C, Summers D.

Mo Med. 2010 Sep-Oct;107(5):333-7. Review.

PMID:
21207786
9.

Acute ischemic stroke therapy.

Henninger N, Kumar R, Fisher M.

Expert Rev Cardiovasc Ther. 2010 Oct;8(10):1389-98. doi: 10.1586/erc.10.128. Review.

PMID:
20936925
10.

Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).

Eissa A, Krass I, Bajorek BV.

J Clin Pharm Ther. 2012 Dec;37(6):620-9. doi: 10.1111/j.1365-2710.2012.01366.x. Review.

PMID:
22708668
11.

Acute ischemic stroke in pediatric patients.

Mittal SO, ThatiGanganna S, Kuhns B, Strbian D, Sundararajan S.

Stroke. 2015 Feb;46(2):e32-4. doi: 10.1161/STROKEAHA.114.007681. Review. No abstract available.

12.

The implementation of intravenous tissue plasminogen activator in acute ischaemic stroke--a scientific position statement from the National Stroke Foundation and the Stroke Society of Australasia.

Ad Hoc Committee representing the National Stroke Foundation and the Stroke Society of Australasia..

Intern Med J. 2009 May;39(5):317-24. doi: 10.1111/j.1445-5994.2009.01938.x. Review.

PMID:
19545242
13.

Intra-arterial thrombolysis: tissue plasminogen activator and other thrombolytic agents.

Samaniego EA, Linfante I, Dabus G.

Tech Vasc Interv Radiol. 2012 Mar;15(1):41-6. doi: 10.1053/j.tvir.2011.12.011. Review.

PMID:
22464301
14.

Alteplase in acute ischemic stroke: putting the guidelines into practice.

Nagaraja N, Adams HP Jr.

CNS Drugs. 2014 Nov;28(11):1035-45. doi: 10.1007/s40263-014-0204-0. Review.

PMID:
25326784
15.

Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.

Maiser SJ, Georgiadis AL, Suri MF, Vazquez G, Lakshminarayan K, Qureshi AI.

Int J Stroke. 2011 Feb;6(1):25-32. doi: 10.1111/j.1747-4949.2010.00537.x. Review.

PMID:
21205237
16.

Acute ischemic stroke update.

Baldwin K, Orr S, Briand M, Piazza C, Veydt A, McCoy S.

Pharmacotherapy. 2010 May;30(5):493-514. doi: 10.1592/phco.30.5.493. Review.

PMID:
20412000
17.

Advances in thrombolytics for treatment of acute ischemic stroke.

Kirmani JF, Alkawi A, Panezai S, Gizzi M.

Neurology. 2012 Sep 25;79(13 Suppl 1):S119-25. Review.

PMID:
23008386
18.

Contemporary acute ischemic stroke therapy with intravenous recombinant tissue plasminogen activator.

Frank JI.

Clin Neurosurg. 2000;46:261-6. Review. No abstract available.

PMID:
10944682
19.

Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset.

Otwell JL, Phillippe HM, Dixon KS.

Am J Health Syst Pharm. 2010 Jul 1;67(13):1070-4. doi: 10.2146/ajhp090501. Review.

PMID:
20554592
20.

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.

Chapman SN, Mehndiratta P, Johansen MC, McMurry TL, Johnston KC, Southerland AM.

Vasc Health Risk Manag. 2014 Feb 24;10:75-87. doi: 10.2147/VHRM.S39213. Review.

Items per page

Supplemental Content

Support Center